Fibroblast Activation Protein Inhibitor Theranostics
Authors:
- 15 June 2022
- journal article
- research article
- Published by Elsevier in PET Clinics
- Vol. 17 (3) , 453-464
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Evaluation of the Radiolabeled Boronic Acid-Based FAP Inhibitor MIP-1232 for Atherosclerotic Plaque ImagingMolecules, 2015
- Extended Structure–Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)Journal of Medicinal Chemistry, 2014
- Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapyProteomics – Clinical Applications, 2014
- Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine ScaffoldACS Medicinal Chemistry Letters, 2013
- Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung CancerClinical Oncology, 2009
- Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor FibroblastsClinical Cancer Research, 2008
- Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptakeJournal of Clinical Investigation, 2006
- Clinical Role of FDG PET in Evaluation of Cancer PatientsRadioGraphics, 2003
- Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal CancerOncology Research and Treatment, 2003
- Labeled 2‐deoxy‐D‐glucose analogs. 18F‐labeled 2‐deoxy‐2‐fluoro‐D‐glucose, 2‐deoxy‐2‐fluoro‐D‐mannose and 14C‐2‐deoxy‐2‐fluoro‐D‐glucoseJournal of Labelled Compounds and Radiopharmaceuticals, 1978